Published : 14 Feb 2018
In a new assignment from a new client Aagami is now poised to support licensing or acquisition of the first and only oral contraceptive specifically designed for millions of overweight and obese women (about 60% of pill users in US). Client is focused on Women’s health and the founder is also a co-inventor of the bestselling contraceptive pill in the US.
This assignment is dedicated to the better health and well-being of the millions of women out there with high BMI and Aagami feels privileged to be able to support such a unique cause with a special segment of the society.
The client has a fantastic product line to offer and Aagami will take the licensing/ acquisition of the IP to large and mid-size companies who are focused on the US and EU markets, with women’s health, as an area of operation/ intended operation. One of the products in the basket itself has an annual sales potential of $700M in the US market